Sample Matrices for Mass Spectrometry-Based Adherence Monitoring: A Systematic Critical Review.

Journal

Therapeutic drug monitoring

ISSN: 1536-3694

Titre abrégé: Ther Drug Monit

Pays: United States

ID NLM: 7909660

Informations de publication

Date de publication:
05 Oct 2023

Historique:

received: 18 05 2023

accepted: 12 07 2023

medline: 6 10 2023

pubmed: 6 10 2023

entrez: 6 10 2023

Statut: aheadofprint

Résumé

Analytical monitoring of adherence using mass spectrometry (MS) plays an important role in clinical toxicology. Unambiguous detection of drugs (of abuse) and/or their metabolites in body fluids is needed to monitor intake of medication as prescribed or to monitor abstinence as a follow-up to detoxification procedures. This study focused on the advantages and disadvantages of different sample matrices used for MS-based adherence monitoring. Relevant articles were identified through a literature search in the PubMed database. English articles published between January 01, 2017, and December 31, 2022, were selected using the keywords "adherence assess*" or "adherence monit*" or "compliance assess*" or "compliance monit*" in combination with "mass spectrom*" in the title or abstract. A total of 51 articles were identified, 37 of which were within the scope of this study. MS-based monitoring was shown to improve patient adherence to prescribed drugs. However, MS analysis may not be able to assess whether treatment was rigorously followed beyond the last few days before the sampling event, except when hair is the sample matrix. For medication adherence monitoring, blood-based analyses may be preferred because reference plasma concentrations are usually available, whereas for abstinence control, urine and hair samples have the advantage of extended detection windows compared with blood. Alternative sample matrices, such as dried blood samples, oral fluid, and exhaled breath, are suitable for at-home sampling; however, little information is available regarding the pharmacokinetics and reference ranges of drug (of abuse) concentrations. Each sample matrix has strengths and weaknesses, and no single sample matrix can be considered the gold standard for monitoring adherence. It is important to have sufficient information regarding the pharmacokinetics of target substances to select a sample matrix in accordance with the desired purpose.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

Relevant articles were identified through a literature search in the PubMed database. English articles published between January 01, 2017, and December 31, 2022, were selected using the keywords "adherence assess*" or "adherence monit*" or "compliance assess*" or "compliance monit*" in combination with "mass spectrom*" in the title or abstract.

RESULTS RESULTS

A total of 51 articles were identified, 37 of which were within the scope of this study. MS-based monitoring was shown to improve patient adherence to prescribed drugs. However, MS analysis may not be able to assess whether treatment was rigorously followed beyond the last few days before the sampling event, except when hair is the sample matrix. For medication adherence monitoring, blood-based analyses may be preferred because reference plasma concentrations are usually available, whereas for abstinence control, urine and hair samples have the advantage of extended detection windows compared with blood. Alternative sample matrices, such as dried blood samples, oral fluid, and exhaled breath, are suitable for at-home sampling; however, little information is available regarding the pharmacokinetics and reference ranges of drug (of abuse) concentrations.

CONCLUSIONS CONCLUSIONS

Each sample matrix has strengths and weaknesses, and no single sample matrix can be considered the gold standard for monitoring adherence. It is important to have sufficient information regarding the pharmacokinetics of target substances to select a sample matrix in accordance with the desired purpose.

Identifiants

DOI: 10.1097/FTD.0000000000001145 PMID: 37798828

pubmed: 37798828

doi: 10.1097/FTD.0000000000001145

pii: 00007691-990000000-00154

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.

Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521–530.

Arvidsson M, Ullah S, Franck J, et al. Drug abuse screening with exhaled breath and oral fluid in adults with substance use disorder. Drug Test Anal. 2018;11:27–32.

Allen KR. Screening for drugs of abuse: which matrix, oral fluid or urine? Ann Clin Biochem. 2011;48:531–541.

Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.

Svensson S, Kjellgren KI, Ahlner J, et al. Reasons for adherence with antihypertensive medication. Int J Cardiol. 2000;76:157–163.

Miller NH, Hill M, Kottke T, et al. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation. 1997;95:1085–1090.

Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445–449.

Wallbach M, Lach N, Stock J, et al. Direct assessment of adherence and drug interactions in patients with hypertensive crisis-A cross-sectional study in the Emergency Department. J Clin Hypertens. 2019;21:55–63.

Gupta P, Patel P, Horne R, et al. How to screen for non-adherence to antihypertensive therapy. Curr Hypertens Rep. 2016;18:89.

Musinguzi N, Muganzi CD, Boum Y II, et al. Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa. AIDS. 2016;30:1121–1129.

Blumenthal J, Pasipanodya EC, Jain S, et al. Comparing self-report pre-exposure prophylaxis adherence questions to pharmacologic measures of recent and cumulative pre-exposure prophylaxis exposure. Front Pharmacol. 2019;10:721.

Larsen KG, Areberg J, Astrom DO. Are self-reported and self-monitored adherence good proxies for reaching relevant plasma concentrations?: experiences from a study of anti-depressants in healthy volunteers. Clin Trials. 2021;18:505–510.

Rentsch KM. Knowing the unknown – state of the art of LCMS in toxicology. Trac Trends Anal Chem. 2016;84:88–93.

Guinan TM, Neldner D, Stockham P, et al. Porous silicon mass spectrometry as an alternative confirmatory assay for compliance testing of methadone. Drug Test Anal. 2017;9:769–777.

Marin SJ, Doyle K, Chang A, et al. One hundred false-positive amphetamine specimens characterized by liquid chromatography time-of-flight mass spectrometry. J Anal Toxicol. 2016;40:37–42.

Maurer HH. Current role of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Anal Bioanal Chem. 2007;388:1315–1325.

Maurer HH, Pfleger K, Weber AA. Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites. 3rd ed. Weinheim: Wiley-VCH; 2007.

Maurer HH. Pitfalls in drug testing by hyphenated low- and high-resolution mass spectrometry. Drug Test Anal. 2020;12:172–179.

Maurer HH. Hyphenated high-resolution mass spectrometry-the “all-in-one” device in analytical toxicology? Anal Bioanal Chem. 2021;413:2303–2309.

Richter LHJ, Jacobs CM, Mahfoud F, et al. Development and application of a LC-HRMS/MS method for analyzing antihypertensive drugs in oral fluid for monitoring drug adherence. Analytica Chim Acta. 2019;1070:69–79.

Gupta P, Patel P, Strauch B, et al. Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence. Hypertension. 2017;70:1042–1048.

Kably B, Billaud EM, Derobertmasure A, et al. Urine N-acetyl-Ser-Asp-Lys-Pro measurement as a versatile biomarker to assess adherence to angiotensin-converting enzyme inhibitors. J Hypertens. 2022;40:348–355.

Danso D, Langman LJ, Jannetto PJ. Targeted opioid screening assay for pain management using high-resolution mass spectrometry. Methods Mol Biol. 2019;1872:41–50.

Jamshidi N, Athavale A, Tremonti C, et al. Evaluation of adherence monitoring in buprenorphine treatment: a pilot study using timed drug assays to determine accuracy of testing. Br J Clin Pharmacol. 2023;89:1938–1947.

Hebel S, Kahn-Woods E, Malone-Thomas S, et al. Brief report: discrepancies between self-reported adherence and a biomarker of adherence in real-world settings. J Acquir Immune Defic Syndr. 2020;85:454–457.

Lalley-Chareczko L, Hiserodt E, Moorthy G, et al. Urine assay to measure tenofovir concentrations in patients taking tenofovir alafenamide. Front Pharmacol. 2020;11:286.

Koenig HC, Mounzer K, Daughtridge GW, et al. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. HIV Med. 2017;18:412–418.

Kim SY, Kim HS, Cheong JC, et al. LC-MS-MS determination of 25 antipsychotic drugs and metabolites in urine for medication compliance monitoring. J Anal Toxicol. 2020;44:784–796.

Vethe NT, Munkhaugen J, Andersen AM, et al. A method for direct monitoring of atorvastatin adherence in cardiovascular disease prevention: quantification of the total exposure to parent drug and major metabolites using 2-channel chromatography and tandem mass spectrometry. Ther Drug Monit. 2019;41:19–28.

Punt AM, Stienstra NA, van Kleef MEA, et al. Screening of cardiovascular agents in plasma with LC-MS/MS: a valuable tool for objective drug adherence assessment. J Chromatogr B. 2019;1121:103–110.

Ritscher S, Hoyer M, Wunder C, et al. Evaluation of the dose-related concentration approach in therapeutic drug monitoring of diuretics and beta-blockers - drug classes with low adherence in antihypertensive therapy. Sci Rep. 2019;9:15652.

Wagmann L, Hemmer S, Caspar AT, et al. Method development for quantitative determination of seven statins including four active metabolites by means of high-resolution tandem mass spectrometry applicable for adherence testing and therapeutic drug monitoring. Clin Chem Lab Med (CCLM). 2020;58:664–672.

Ritscher S, Hoyer M, Georges C, et al. Benefit of serum drug monitoring complementing urine analysis to assess adherence to antihypertensive drugs in first-line therapy. PLoS One. 2020;15:e0237383.

Ritscher S, Georges C, Wunder C, et al. Assessment of adherence to diuretics and beta-blockers by serum drug monitoring in comparison to urine analysis. Blood Press. 2020;29:291–298.

Wagmann L, Vollmer AC, Lauder L, et al. Assessing adherence to antihypertensive medication by means of dose-dependent reference plasma concentration ranges and ultra-high performance liquid chromatography-ion trap mass spectrometry analysis. Molecules. 2021;26:1495.

Pu F, Pandey S, Bushman LR, et al. Direct quantitation of tenofovir diphosphate in human blood with mass spectrometry for adherence monitoring. Anal Bioanal Chem. 2020;412:1243–1249.

Jacobs CM, Kunz M, Mahfoud F, et al. Evaluation and analytical applicability of a novel volumetric absorptive microsampling strategy for adherence monitoring of antihypertensive drugs by means of LC-HRMS/MS. Analytica Chim Acta. 2021;1187:339137.

Jacobs CM, Kunz M, Mahfoud F, et al. Closing the gap—development of an analytical methodology using volumetric absorptive microsampling of finger prick blood followed by LC-HRMS/MS for adherence monitoring of antihypertensive drugs. Anal Bioanal Chem. 2023;415:167–177.

Jacobs CM, Wagmann L, Meyer MR. Development, validation, and application of a quantitative volumetric absorptive microsampling-based method in finger prick blood by means of LC-HRMS/MS applicable for adherence monitoring of antipsychotics. Anal Bioanal Chem. 2021;413:1729–1737.

Duthaler U, Berger B, Erb S, et al. Automated high throughput analysis of antiretroviral drugs in dried blood spots. J MA Spectrom. 2017;52:534–542.

Schauer AP, Sykes C, Cottrell ML, et al. Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots. J Pharm Biomed Anal. 2018;149:40–45.

Lierheimer S, Beck O, Keller T, et al. Hydromorphone and codeine concentrations in oral fluid specimens from patients receiving substitution therapy with Substitol (morphine sulfate). Drug Test Anal. 2021;13:1743–1748.

Bottcher M, Kuhne D, Beck O. Compliance testing of patients in ADHD treatment with lisdexamphetamine (Elvanse®) using oral fluid as specimen. Clin Mass Spectrom. 2019;14:99–105.

Neumann J, Beck O, Dahmen N, et al. Potential of oral fluid as a clinical specimen for compliance monitoring of psychopharmacotherapy. Ther Drug Monit. 2018;40:245–251.

Carlsson S, Olsson R, Lindkvist I, et al. Application of drug testing using exhaled breath for compliance monitoring of drug addicts in treatment. Scand J Clin Lab Invest. 2015;75:156–161.

Wu Y, Chu L, Yang H, et al. Simultaneous determination of 6 antiretroviral drugs in human hair using an LC-ESI+-MS/MS method: application to adherence assessment. Ther Drug Monit. 2021;43:756–765.

Gilliland WM Jr., Prince HMA, Poliseno A, et al. Infrared matrix-assisted laser desorption electrospray ionization mass spectrometry imaging of human hair to characterize longitudinal profiles of the antiretroviral maraviroc for adherence monitoring. Anal Chem. 2019;91:10816–10822.

Gandhi M, Devi S, Bacchetti P, et al. Measuring adherence to antiretroviral therapy via hair concentrations in India. J Acquir Immune Defic Syndr. 2019;81:202–206.

Koss CA, Liu AY, Castillo-Mancilla J, et al. Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring. AIDS. 2018;32:2189–2194.

Thaden JT, Gandhi M, Okochi H, et al. Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination. AIDS. 2018;32:F1–F4.

Mwangi JN, Gilliland WM Jr., White N, et al. MA spectroscopy imaging of hair strands captures short-term and long-term changes in emtricitabine adherence. Antimicrob Agents Chemother. 2022;66:e0217621.

Binz TM, Williner E, Strajhar P, et al. Chiral analysis of amphetamines in hair by liquid chromatography-tandem mass spectrometry: compliance-monitoring of attention deficit hyperactivity disorder (ADHD) patients under Elvanse® therapy and identification after controlled low-dose application. Drug Test Anal. 2018;10:254–261.

Ransohoff JR, Petrides AK, Piscitello GJ, et al. Urine is superior to oral fluid for detecting buprenorphine compliance in patients undergoing treatment for opioid addiction. Drug and Alcohol Depend. 2019;203:8–12.

Luginbuhl M, Weinmann W, Butzke I, et al. Monitoring of direct alcohol markers in alcohol use disorder patients during withdrawal treatment and successive rehabilitation. Drug Test Anal. 2019;11:859–869.

Niu X, Kubiak RW, Siriprakaisil O, et al. Tenofovir-Diphosphate in dried blood spots vs tenofovir in urine/plasma for oral preexposure prophylaxis adherence monitoring. Open Forum Infect Dis. 2022;9:ofac405.

Lane D, Lawson A, Burns A, et al. Nonadherence in hypertension: how to develop and implement chemical adherence testing. Hypertension. 2022;79:12–23.

Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit. 2004;26:200–205.

Kraemer T, Paul LD. Bioanalytical procedures for determination of drugs of abuse in blood. Anal Bioanal Chem. 2007;388:1415–1435.

Schulz M, Schmoldt A, Andresen-Streichert H, et al. Revisited: therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care. 2020;24:195.

Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963;32:338–343.

Capiau S, Veenhof H, Koster RA, et al. Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring. Ther Drug Monit. 2019;41:409–430.

Robijns K, Koster RA, Touw DJ. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin Pharmacokinet. 2014;53:1053.

Pandya HC, Spooner N, Mulla H. Dried blood spots, pharmacokinetic studies and better medicines for children. Bioanalysis. 2011;3:779–786.

Sadones N, Capiau S, De Kesel PM, et al. Spot them in the spot: analysis of abused substances using dried blood spots. Bioanalysis. 2014;6:2211–2227.

Choo RE, Huestis MA. Oral fluid as a diagnostic tool. Clin Chem Lab Med (CCLM). 2004;42:1273–1287.

Crouch DJ. Oral fluid collection: the neglected variable in oral fluid testing. Forensic Sci Int. 2005;150:165–173.

Trefz P, Kamysek S, Fuchs P, et al. Drug detection in breath: non-invasive assessment of illicit or pharmaceutical drugs. J Breath Res. 2017;11:024001.

Beck O, Sandqvist S, Franck J. Demonstration that methadone is being present in the exhaled breath aerosol fraction. J Pharm Biomed Anal. 2011;56:1024–1028.

Beck O, Stephanson N, Sandqvist S, et al. Detection of drugs of abuse in exhaled breath using a device for rapid collection: comparison with plasma, urine and self-reporting in 47 drug users. J Breath Res. 2013;7:026006.

Tinglev AD, Ullah S, Ljungkvist G, et al. Characterization of exhaled breath particles collected by an electret filter technique. J Breath Res. 2016;10:026001.

Barbosa J, Faria J, Carvalho F, et al. Hair as an alternative matrix in bioanalysis. Bioanalysis. 2013;5:895–914.

Villain M, Cirimele V, Kintz P. Hair analysis in toxicology. Clin Chem Lab Med (CCLM). 2004;42:1265–1272.

Cooper GA. Hair testing is taking root. Ann Clin Biochem. 2011;48:516–530.

Vogliardi S, Tucci M, Stocchero G, et al. Sample preparation methods for determination of drugs of abuse in hair samples: a review. Analytica Chim Acta. 2015;857:1–27.

Gareri J, Klein J, Koren G. Drugs of abuse testing in meconium. Clinica Chim Acta. 2006;366:101–111.

Madej KA. Analysis of meconium, nails and tears for determination of medicines and drugs of abuse. Trac Trends Anal Chem. 2010;29:246–259.

Moore C, Negrusz A, Lewis D. Determination of drugs of abuse in meconium. J Chromatogr B: Biomed Sci Appl. 1998;713:137–146.

D'Avila FB, Ferreira PC, Salazar FR, et al. Analysis of cocaine/crack biomarkers in meconium by LC-MS. J Chromatogr B. 2016;1012-1013:113–117.

Browne SP, Tebbett IR, Moore CM, et al. Analysis of meconium for cocaine in neonates. J Chromatogr B: Biomed Sci Appl. 1992;575:158–161.

Wozniak MK, Banaszkiewicz L, Aszyk J, et al. Development and validation of a method for the simultaneous analysis of fatty acid ethyl esters, ethyl sulfate and ethyl glucuronide in neonatal meconium: application in two cases of alcohol consumption during pregnancy. Anal Bioanal Chem. 2021;413:3093–3105.

ElSohly MA, Stanford DF, Murphy TP, et al. Immunoassay and GC-MS procedures for the analysis of drugs of abuse in meconium. J Anal Toxicol. 1999;23:436–445.

Wagmann L, Jacobs CM, Meyer MR. New psychoactive substances: which biological matrix is the best for clinical toxicology screening? Ther Drug Monit. 2022;44:599–605.